Cesca Therapeutics Set to Join Russell Microcap® Index
June 23 2017 - 10:00AM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
is set to join the Russell Microcap® Index at the conclusion of the
Russell U.S. Indexes annual reconstitution, effective after the
U.S. markets open on June 26, 2017.
Membership in the Russell Microcap® Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
“Inclusion in the Russell Microcap® Index is a
significant achievement for Cesca Therapeutics and is a testament
to the progress we have made in building a world-class developer of
automated technologies for cell-based therapeutics,” said Dr.
Xiaochun “Chris” Xu, chairman and interim chief executive officer.
“The Russell indexes are broadly followed by the investment
community, and we look forward to the increased visibility at this
important time in our company’s evolution. Cell-based therapies
hold great promise in addressing many areas of significant unmet
need, including immuno-oncology, and our technologies are poised to
play a significant part in the continuing evolution of this
exciting field.”
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $8.4
trillion in assets are benchmarked against Russell’s US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap®
Index and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About Cesca Therapeutics Inc.Cesca is a leading
regenerative medicine company that develops, commercializes and
markets a range of automated technologies for cell-based
therapeutics. Its device division, ThermoGenesis, provides a full
suite of solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. Cesca is
also leveraging its proprietary AutoXpress® technology platform to
develop autologous stem cell-based therapies that address
significant unmet needs in the vascular, cardiology and orthopedic
markets.
Cesca is an affiliate of the BoyaLife Group, a
China-based industry research alliance encompassing top research
institutions for stem cell and regenerative medicine.
About FTSE Russell:FTSE Russell
is a leading global index provider creating and managing a wide
range of indexes, data and analytic solutions to meet client needs
across asset classes, style and strategies. Covering 98% of the
investable market, FTSE Russell indexes offer a true picture of
global markets, combined with the specialist knowledge gained from
developing local benchmarks around the world.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $12.5 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create investment funds, ETFs, structured products and index-based
derivatives. FTSE Russell indexes also provide clients with tools
for asset allocation, investment strategy analysis and risk
management.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on index innovation and
customer partnership applying the highest industry standards and
embracing the IOSCO Principles. FTSE Russell is wholly owned by
London Stock Exchange Group.
For more information, visit
www.ftserussell.com
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024